Navigation Links
Second Phase III Study of Avastin in 1st Line Metastatic Breast Cancer Meets its Primary Endpoint
Date:2/12/2008

aclitaxel alone.

About the BO17708 study

BO17708 is an international phase III trial which randomized 736 patients who did not receive previous chemotherapy for their metastatic breast cancer to one of three groups;

-- Avastin 7.5 mg/kg every 3 weeks in combination with docetaxel

-- Avastin 15 mg/kg every 3 weeks in combination with docetaxel

-- docetaxel + placebo as control arm

The primary objective of the study was to demonstrate superiority in progression-free survival of both Avastin containing treatment arms compared to the control arm. Secondary endpoints for the study included overall survival, response rate, duration of response, quality of life, safety and tolerability.

About Avastin

Data from the comprehensive Avastin cancer clinical development programme have resulted in approvals in advanced colorectal, breast, lung, and kidney cancer:

-- February 2004 (US) and January 2005 (EU) -- first-line treatment in

patients with metastatic colorectal cancer (CRC).

-- June 2006 (US) -- second-line treatment in patients with metastatic

CRC.

-- October 2006 (US) -- first-line treatment in patients with advanced

non-small cell lung cancer (NSCLC).

-- March 2007 (EU) -- first-line treatment in patients with metastatic

breast cancer.

-- April 2007 (Japan) -- treatment in patients with recurrent or advanced

CRC.

-- August 2007 (EU) -- first-line treatment in patients with advanced

NSCLC.

-- December 2007 (EU) -- first-line treatment in patients with advanced

RCC.

-- January 2008 (EU) -- first and later-line treatment in patients with

metastatic CRC in combination with any chemotherapy.

All trademarks used or mentioned in this release are legally protected.

Additional information

To access video clips about Avastin, in broadcast standard, free of charge, please go
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. Second Thoughts about Fluoride, Reports Scientific American
5. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
6. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
7. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
8. Immtech Reports Fiscal Second Quarter 2008 Results
9. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
10. Rcadias COR Analyzer Family of Products Receives Second FDA Clearance
11. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Calif. , Aug. 31, 2015 ... flow cytometry is experiencing a rise in active ... demand in underdeveloped nations to quantitate CD4 cell ... Logo - http://photos.prnewswire.com/prnh/20150831/262206LOGO ... of the Global Flow Cytometry Market ( http://www.frost.com/nf0e ...
(Date:8/31/2015)... , Aug. 31, 2015  The departments of Drug ... today at Gaudenzia Concept 90 to raise awareness for ... crisis in Pennsylvania and help ... focus on recovery through the Building Bridges to ... are dying every day to a disease that is ...
(Date:8/31/2015)... , Aug. 31, 2015  Diplomat Pharmacy, Inc. (NYSE: ... that Phil Hagerman , Chairman & CEO, and ... conferences. Mr. Hagerman and Mr. Whelan are ... in Boston on Wednesday, September 9, ... Mr. Whelan are also scheduled to participate in the Robert ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2
... OrbusNeich today announced that six-month clinical follow-up data show the safety ... balloon (Sequent Please®, B.Braun) followed by implantation of the company,s Genous ... , , , ... investigator-initiated, single center, all-comers POTENT ( P aclitaxel-eluting ball O on ...
... Pfizer Inc. (NYSE: PFE ) announced today that based ... be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for ... States and that it will be voluntarily withdrawing the new drug ... , , ...
Cached Medicine Technology:Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 2Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 2Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 4Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 5Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 6
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... In an ... from the Plastic and Reconstructive Surgery Global Open Journal that discusses the future of ... article discussed how, in the future, customized implants, prosthetics, and other 3-D printed tools ...
(Date:8/31/2015)... ... August 31, 2015 , ... David L. Chalnick, M.D., ... of the first doctors in the area to perform minimally invasive hip replacement ... impressive: faster recovery, decreased immediate and long-term pain, and an accelerated return to ...
(Date:8/31/2015)... Scotch Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... years as an “NJ Top Doc.” , At OSSMC, Dr. Kovatis treats all surgical ... general orthopedics and traumatic injuries to the entire musculoskeletal system, excluding the spine. , ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... diagnostic services, and others—to hold down costs? , In a commentary for ... of HealthReveal, presents the concept of “clinical efficacy,” which would bind parties together ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... ... the 2015 ABBY Awards, at the 16th Innovations in Healthcare(SM) Awards Event ... Adaptive Business Leaders (ABL) Organization , recognizes innovative organizations and individuals who ...
Breaking Medicine News(10 mins):Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8
... 2 Rochester Medical Corporation (Nasdaq: ROCM ) ... 31, 2008.The Company reported sales of $8,436,000 for the current ... year. It also reported net income of $54,000 or ... or $.02 per diluted share for the first quarter of ...
... Calif., Feb. 2 Digirad Corporation (Nasdaq: ... and personnel and equipment leasing services that improve patient ... it has sold the assets related to three northern ... with Rancho Santa Fe, Calif.-based MD Office Solutions calls ...
... More exposure meant more symptoms, study found , , MONDAY, ... hours watching television are at higher risk for depression ... significantly greater odds of being depressed seven years later, ... television viewed, according to a report involving more than ...
... for Quality,Assurance (NCQA) has awarded Unison Health Plan of ... program through December 2011. The plan serves,more than ... is based on how well a health plan ensures ... the health,plan,s core systems and processes, but also the ...
... are heavy users of marijuana are more likely ... to a new study. Pediatric researchers found abnormalities ... regions involved in memory, attention, decision-making, language and ... concern because adolescence is a crucial period for ...
... Post-Katrina flooded homes may contain harmful levels of ... mold films, and aerosols may also have exposed residents, ... without the need for direct skin contact, according to ... (Volume 26, Number 3) of Environmental Engineering Science, a ...
Cached Medicine News:Health News:Rochester Medical Reports First Quarter Results 2Health News:Rochester Medical Reports First Quarter Results 3Health News:Rochester Medical Reports First Quarter Results 4Health News:Rochester Medical Reports First Quarter Results 5Health News:Rochester Medical Reports First Quarter Results 6Health News:Rochester Medical Reports First Quarter Results 7Health News:Rochester Medical Reports First Quarter Results 8Health News:Digirad Corporation Sells Northern California Service Hubs 2Health News:Teen TV Time Tied to Adult Depression 2Health News:Teen TV Time Tied to Adult Depression 3Health News:Unison Health Plan of Ohio Accredited by NCQA 2Health News:Heavy marijuana use may damage developing brain in teens, young adults 2Health News:Newly Described Contaminant Sources in Katrina-Flooded Homes Pose Health Risks 2
... When myocardial infarction is suspected, ... sensitive rapid assay allows rapid ... troponin T from a single ... result is available within minutes ...
The Polygraf ID multi-parametric recorder works with POLYGRAM NET analysis software to create a unique interface that combines web-style navigation, graphical presentation and intuitive design to del...
... the industry standard high intensity 300 Watt Xenon ... price. A universal turret on the front panel ... Olympus, Storz, ACMI/Circon and Wolf cable connectors., ,Front ... timer. The White Sun will quickly illuminate at ...
... is intended for determination of human NGAL ... tissue extracts or culture media., NGAL (neutrophil ... urine, as early as 2 hours after ... processes. NGAL expression in plasma or urine ...
Medicine Products: